תרופן 18 מג Israel - ebraică - Ministry of Health

תרופן 18 מג

taro international ltd, israel - methylphenidate hydrochloride - טבליות עם שחרור נרחב - methylphenidate hydrochloride 18 mg - methylphenidate

תרופן 27 מג Israel - ebraică - Ministry of Health

תרופן 27 מג

taro international ltd, israel - methylphenidate hydrochloride - טבליות עם שחרור נרחב - methylphenidate hydrochloride 27 mg - methylphenidate

תרופן 36 מג Israel - ebraică - Ministry of Health

תרופן 36 מג

taro international ltd, israel - methylphenidate hydrochloride - טבליות עם שחרור נרחב - methylphenidate hydrochloride 36 mg - methylphenidate

תרופן 54 מג Israel - ebraică - Ministry of Health

תרופן 54 מג

taro international ltd, israel - methylphenidate hydrochloride - טבליות עם שחרור נרחב - methylphenidate hydrochloride 54 mg - methylphenidate

רקויפ מודוטאב 2 מ"ג Israel - ebraică - Ministry of Health

רקויפ מודוטאב 2 מ"ג

glaxo smith kline (israel) ltd - ropinirole as hydrochloride 2 mg - film coated tablets - prolonged release - ropinirole - ropinirole is indicated for the treatment of parkinson's disease. ropinirole is effective as early therapy in patients requiring dopaminergic therapy. as adjunctive treatment to l-dopa, ropinirole enhances the efficacy of l-dopa, including control of "on-off" fluctuations and "end of dose" effects associated with chronic l-dopa therapy and permits reduction in daily l-dopa dose.

רקוויפ מודוטאב 2 מג Israel - ebraică - Ministry of Health

רקוויפ מודוטאב 2 מג

glaxo smith kline (israel) ltd - ropinirole as hydrochloride - טבליות מצופות פילם - שחרור ממושך - ropinirole as hydrochloride 2 mg - ropinirole - ropinirole - ropinirole is indicated for the treatment of parkinson's disease. ropinirole is effective as early therapy in patients requiring dopaminergic therapy. as adjunctive treatment to l-dopa, ropinirole enhances the efficacy of l-dopa, including control of "on-off" fluctuations and "end of dose" effects associated with chronic l-dopa therapy and permits reduction in daily l-dopa dose.

רקויפ מודוטאב 8 מ"ג Israel - ebraică - Ministry of Health

רקויפ מודוטאב 8 מ"ג

glaxo smith kline (israel) ltd - ropinirole as hydrochloride 8 mg - film coated tablets - prolonged release - ropinirole - ropinirole is indicated for the treatment of parkinson's disease. ropinirole is effective as early therapy in patients requiring dopaminergic therapy. as adjunctive treatment to l-dopa, ropinirole enhances the efficacy of l-dopa, including control of "on-off" fluctuations and "end of dose" effects associated with chronic l-dopa therapy and permits reduction in daily l-dopa dose.

רקוויפ מודוטאב 8 מג Israel - ebraică - Ministry of Health

רקוויפ מודוטאב 8 מג

glaxo smith kline (israel) ltd - ropinirole as hydrochloride - טבליות מצופות פילם - שחרור ממושך - ropinirole as hydrochloride 8 mg - ropinirole - ropinirole - ropinirole is indicated for the treatment of parkinson's disease. ropinirole is effective as early therapy in patients requiring dopaminergic therapy. as adjunctive treatment to l-dopa, ropinirole enhances the efficacy of l-dopa, including control of "on-off" fluctuations and "end of dose" effects associated with chronic l-dopa therapy and permits reduction in daily l-dopa dose.

רקויפ מודוטאב 4 מ"ג Israel - ebraică - Ministry of Health

רקויפ מודוטאב 4 מ"ג

glaxo smith kline (israel) ltd - ropinirole as hydrochloride 4 mg - film coated tablets - prolonged release - ropinirole - ropinirole is indicated for the treatment of parkinson's disease. ropinirole is effective as early therapy in patients requiring dopaminergic therapy. as adjunctive treatment to l-dopa, ropinirole enhances the efficacy of l-dopa, including control of "on-off" fluctuations and "end of dose" effects associated with chronic l-dopa therapy and permits reduction in daily l-dopa dose.

רקוויפ מודוטאב 4 מג Israel - ebraică - Ministry of Health

רקוויפ מודוטאב 4 מג

glaxo smith kline (israel) ltd - ropinirole as hydrochloride - טבליות מצופות פילם - שחרור ממושך - ropinirole as hydrochloride 4 mg - ropinirole - ropinirole - ropinirole is indicated for the treatment of parkinson's disease. ropinirole is effective as early therapy in patients requiring dopaminergic therapy. as adjunctive treatment to l-dopa, ropinirole enhances the efficacy of l-dopa, including control of "on-off" fluctuations and "end of dose" effects associated with chronic l-dopa therapy and permits reduction in daily l-dopa dose.